Navigation Links
Watson Confirms Renvela® for Oral Suspension Patent Challenge
Date:7/12/2010

MORRISTOWN, N.J., July 12 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market sevelamer carbonate for oral suspension, 0.8g and 2.4g per packet.  Watson's sevelamer carbonate for oral suspension product is the generic version of Genzyme's Renvela® for Oral Suspension.  Renvela ® is a phosphate binder indicated for the control of serum phosphorus in patients with chronic kidney disease who are on dialysis.

Genzyme Corporation filed suit against Watson on July 9, 2010 in the United States District Court for the District of Maryland seeking to prevent Watson from commercializing its product prior to the expiration of U.S. Patent No. 5,667,775.  Genzyme's suit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Watson's ANDA for up to 30 months or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.  Based on available information, Watson believes it may be a first applicant to file an ANDA requesting approval of a generic version of Renvela®  for oral suspension, and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity for this dosage form.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company.  The Company is engaged in the development, manufacturing, marketing and dist
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Watson to Host Conference Call and Webcast to Discuss Second Quarter 2010 Earnings
2. Watson Completes Acquisition of CRINONE® and PROCHIEVE® Product Line and Shares of Columbia Laboratories
3. Watsons Generic Prograf® 5 mg Receives FDA Approval
4. Watson Launches Generic Exelon®
5. Watson Confirms Columbia Laboratories Shareholder Approval of Proposed Acquisition of Progesterone-related Assets
6. Watson to Present at the Wells Fargo Securities 2010 Healthcare Conference
7. Watson Confirms Columbia Laboratories Filing of Definitive Proxy Relating to Watsons Acquisition of U.S. Rights to CRINONE® Progesterone Gel Product Line
8. Watsons Generic VALTREX® 500 mg and 1000 mg Receives FDA Approval
9. Watson Launches Generic Version of LIPITOR® in Canada
10. Watson to Present at the 2010 Citi Investment Research Global Healthcare Conference
11. Watson Reaches Settlement with Teva Over Seasonale(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015  Chiasma, Inc. (NASDAQ: CHMA ), ... for the orphan condition acromegaly, today reported financial ... 2015 and provided a corporate update. ... time for Chiasma, as we successfully completed our ... first New Drug Application (NDA) has been accepted ...
(Date:8/31/2015)... 2015 With increasing clinical applications, the ... rise in active partnerships. The primary reason for ... quantitate CD4 cell markers in human immunodeficiency virus ... New analysis from Frost ... Market ( http://www.frost.com/nf0e ), finds the market earned ...
(Date:8/31/2015)... Aug. 31, 2015  The departments of Drug and ... at Gaudenzia Concept 90 to raise awareness for International ... in Pennsylvania and help more ... on recovery through the Building Bridges to Recovery ... dying every day to a disease that is fully ...
Breaking Medicine Technology:Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 2Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 3Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 4Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 5Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 6Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 7Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 8Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 9Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 2Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 3Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 4Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2
... Identify Unique microRNA Signatures That Will ... Project Will Leverage Rosetta Genomics, Proprietary microRNA Extraction, and Quantification Technologies, ... and Experience ... Patients With High Risk, of Recurrence, who may Benefit From Adjuvant ...
... Accrual and Expansion Plans for SB-509-701 Phase 2 Clinical Trial for ... ... Neuropathy, SAN FRANCISCO, June 6 Sangamo BioSciences,Inc. (Nasdaq: SGMO ... trial (SB-509-701) in subjects with moderate to,severe diabetic neuropathy. Additionally, based upon ...
Cached Medicine Technology:Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer 2Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer 3Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer 4Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer 5Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs 2Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs 3Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs 4Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs 5
(Date:8/31/2015)... Los Angeles, CA (PRWEB) , ... August 31, 2015 , ... ... August 16 by CDA Press, the expert guest author addressed the topic of treating ... The author explained that, while steroids were shown to slightly improve physical function in ...
(Date:8/31/2015)... ... August 31, 2015 , ... Wound Care Advantage, a leader ... Introduction to Hyperbaric Medicine Course. The next UHMS approved 40-hour Introduction to Hyperbaric ... in Long Beach, CA. The meeting is open for registration from physicians, clinicians ...
(Date:8/31/2015)... Metamora, Michigan (PRWEB) , ... August 31, 2015 ... ... launched a new weight management program that is unique to the Lake Orion ... in Oakland and Macomb County. , WEmovestrong’s weight management program will incorporate ...
(Date:8/31/2015)... Michigan (PRWEB) , ... August 31, 2015 , ... ... pre and postnatal fitness classes. , Starting September 1st they are ... called "The Mom Bod" and "Healthy Body, Healthy Baby." , More information can ...
(Date:8/31/2015)... Angeles, CA (PRWEB) , ... August 31, 2015 , ... ... start from and those who are interested in learning more about the procedure beyond ... Parsa Mohebi. , Internationally recognized hair transplant surgeon Parsa Mohebi will be on ...
Breaking Medicine News(10 mins):Health News:Article on Steroid Use for Back Pain Highlights the Effectiveness of Surgery in Treating Disk Pain, says Dr. Seyed M. Rezaian 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 4Health News:Watch a Live Hair Transplant at Parsa Mohebi Hair Restoration’s Open House 2
... agent selumetinib has shown promising results in people with ... led by cancer researchers at The Ohio State University. ... protein called MEK, which cancer cells need to proliferate ... lining the bile ducts and gall bladder. About 100,000 ...
... By Kathleen Doheny HealthDay Reporter , MONDAY, ... that report the greatest number of satisfied inhabitants also ... Seemingly contradictory, the findings are probably explained by ... constantly compare oneself to others. "Deep down we ...
... will gather at Rice University,s Shepherd School of Music ... cognition and behavior and present the latest research findings ... a series of in-depth morning seminars, the scientific researchers ... the musicians learn concurrently about brain morphology, music perception ...
... MONDAY, April 25 (HealthDay News) -- New research suggests that ... regulating a brain wave known as the alpha rhythm, which ... small study, researchers found that those participants using meditation were ... told where to direct their attention -- after they finished ...
... association between computer and Internet use in adolescents and ... drunkenness and unprotected sex. "This research is based ... engaged in a behaviour is a way of learning ... candidate in School of Kinesiology and Health Studies. "Since ...
... examines the ion selectivity of cation-selective channels and transporters. ... the Journal of General Physiology ( www.jgp.org ... his introduction, a key tool in most recent studies ... which emphasize the fluid-like features of the selectivity filter ...
Cached Medicine News:Health News:Targeted agent selumetinib shows promise in biliary cancer 2Health News:'Happiest' States Show Highest Suicide Rates: Study 2Health News:'Happiest' States Show Highest Suicide Rates: Study 3Health News:Musicians and scientists to research mind and music at Rice University conference 2Health News:Meditation May Help Brain Block Out Distractions 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: